High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 100; no. 6; pp. e223 - e225
Main Authors Karimi, Mohsen, Nilsson, Christer, Dimitriou, Marios, Jansson, Monika, Matsson, Hans, Unneberg, Per, Lehmann, Sören, Kere, Juha, Hellström-Lindberg, Eva
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.06.2015
Subjects
acute myeloid leukemia
Adult
Aged
Aged, 80 and over
Cells, Cultured
Cohort Studies
Female
Genetic Testing - methods
high-throughput mutational screening
High-Throughput Screening Assays - methods
Humans
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Male
Medicin och hälsovetenskap
Middle Aged
Molecular Genetics
Molekylär genetik
Mutation - genetics
myelodysplastic syndromes
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - mortality
Neoplasms, Second Primary - diagnosis
Neoplasms, Second Primary - genetics
Online Only
Registries
secondary
Survival Rate - trends
therapy-related
secondary
acute myeloid leukemia
high-throughput mutational screening
therapy-related
myelodysplastic syndromes
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2014.118034